Boston — Fleshing out the menu for its Evidence biochip systems, Randox plans to launch eight new panels this month for applications such as drugs of abuse, cerebral disorders, colorectal cancer, and cardiovascular disease.

The availability of the new content-specific chips will greatly expand the Crumlin, UK-based company's current offering for its Evidence systems, and makes good on earlier promises by management to grow its biochip portfolio by this spring, (see BAN 12/14/2005).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.

Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.